Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01845298 · ClinicalTrials.gov registry record · NA
Immune Activation and Drug Absorption in HIV-Infected Patients
A NA study of HIV Infection, sponsored by Drexel University.
- Completed
- Registry status
- NA
- Development phase
- 7
- Enrollment target
- 1
- Study location
NCT01845298 is a NA study of HIV Infection that has completed, run by Drexel University. The registered enrollment target is 7 participants, below the 243-participant average among 73 other HIV Infection trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01845298, a NA study of HIV Infection, has completed, sponsored by Drexel University.
- COMPLETED
- Registry status
- NA
- Development phase
- 7 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators' objective is to describe the variability of rifampicin absorption, markers of inflammation and gut damage, intestinal absorptive capacity, and intestinal permeability among HIV-infected volunteers. Rifampicin is the least well absorbed of the first-line anti-tuberculosis drugs. Rifampicin malabsorption is frequently observed in HIV-infected patients with active tuberculosis, but cannot be predicted by patient factors such as CD4+ T cell count, viral load, or the presence of diarrhea. The mechanisms for rifampicin malabsorption in HIV-infected patients are unknown. An understanding of mechanisms for rifampicin malabsorption could eventually lead to new therapeutic targets, with the ultimate goal of improving HIV/tuberculosis treatment outcomes.
Conditions Studied
Interventions
- DRUG Rifampicin 600 mg
Study Locations (1)
Pennsylvania
- Drexel University College of Medicine - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2014-06 |
| Est. Completion | 2016-03-14 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01845298
The ClinicalTrials.gov registry entry for NCT01845298 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 243-participant average among 73 other HIV Infection trials with a reported enrollment target (97% lower). The listed sponsor is Drexel University, which has 92 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV Infection appearing as the primary indexed condition, and to 1 intervention - of which Rifampicin 600 mg is the first listed.
NCT01845298 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01845298 about?
NCT01845298 is a clinical study titled "Immune Activation and Drug Absorption in HIV-Infected Patients". The investigators' objective is to describe the variability of rifampicin absorption, markers of inflammation and gut damage, intestinal absorptive capacity, and intestinal permeability among HIV-infected volunteers. Rifampicin is the least well absorbed of the first-line anti-tuberculosis drugs. Ri...
What is the current status of trial NCT01845298?
This trial is currently completed. It is a NA study. The enrollment target is 7 participants. The study started on 2014-06. Estimated completion is 2016-03-14.
What conditions does trial NCT01845298 study?
This clinical trial studies the following conditions: HIV Infection.
What interventions are being tested in trial NCT01845298?
The interventions under investigation include: Rifampicin 600 mg (DRUG).
Who is sponsoring clinical trial NCT01845298?
This trial is sponsored by Drexel University, which has 92 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01845298 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
HIV+ Deceased Donor Heart Transplant Study for HIV+ Recipients
RECRUITING · NA
-
Impact of Behavior Modification Interventions and Lung Cancer Screening on Smoking Cessation in People Living With HIV: A Feasibility Study
RECRUITING · NA
-
Suubi-Mhealth: A Mobile Health Intervention to Address Depression Among Youth
RECRUITING · NA
-
The Role of the Gastrointestinal-associated Lymphoid Tissue in the Cure of HIV Infection
RECRUITING · NA
-
Anal Cytology Collection Procedures in Predicting High-Grade Anal Dysplasia in Men Who Have Sex With Men
ACTIVE NOT RECRUITING · NA
-
Technology-based Training Tool for PHAT Life
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.